January 20, 2006 13:35 ET

Nymox AlzheimAlert™ Findings To Be Presented at National Meeting

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Jan 20, 2006) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that positive data from successful clinical studies of the Company's AlzheimAlert™ test will be presented at the Annual Symposium of the American Medical Directors Association in Dallas on March 16, 2006. Study results will be presented by first author Dr. Ira Goodman of the Orlando Regional Healthcare System. Dr. Goodman was a principal investigator in the reported studies.

Dr. Goodman is Chairman of the Department of Neurology of the Orlando Regional Healthcare System, and is Director of the Memory Disorder Clinic and Associate Clinical Professor in the Department of Medicine at the University of Florida School of Medicine. Dr Goodman is also Faculty of Florida State University Medical School, and member of the Research Sub-committee of the Alzheimer's Disease Initiative of the Department of Elder Affairs of the State of Florida.

The AlzheimAlert™ test is a urine based diagnostic aid for Alzheimer's disease. It is the only proven accurate non-invasive AD test technology available. The test has the CE Mark, allowing it to be marketed in Europe, and is CLIA certified as a laboratory test service which is available in the U.S. Nymox currently has numerous initiatives underway for the AlzheimAlert™ testing technology, including marketing and distribution overseas, and global product development.

There are an estimated 4.5 million people with Alzheimer's disease in the United States alone; by 2050 this number is projected to increase almost three times to 13.2 million. Worldwide estimates of the current number of people with Alzheimer's disease range from 15 to 20 million. The annual national direct and indirect costs of caring for Alzheimer patients in the U.S. alone are estimated at $100 billion. The human toll on patients, families and caregivers is incalculable.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX